# HEOR Portfolio

This page presents a collection of health economic models
developed for HTA-style decision-making.

---

## Cost-Effectiveness Analysis (R)
- [R Script](cost-effectiveness-plane/Cost-Effectiveness%20Plane.R)
- [Fictional Dataset](cost-effectiveness-plane/cep_data.csv)
- [Cost-Effectiveness Plane](cost-effectiveness-plane/Cost-Effectiveness%20Plane.png)
![Cost-Effectiveness Plane](cost-effectiveness-plane/Cost-Effectiveness%20Plane.png)
*Illustrates Cost-Effectiveness of Treatment Options under NICE's Willingness-To-Pay Thresholds (£20,000-30,000 per QALY).*


---

## Budget Impact Analysis (Excel) - Teprotumumab to Treat Thyroid Eye Disease (TED)
- [Teprotumumab Budget Impact Model](budget-impact-analysis/Teprotumumab%20BIA.xlsx)

### 1) Epidemiology and Target Population

![Epidemiology and target population cascade](budget-impact-analysis/Epidemiology_Teprotumamb.png)

*Target population estimation for active moderate–severe TED in the UK, using an epidemiology cascade (population → Graves’ disease → TED prevalence → severity → eligibility), with prevalent and incident patients reported.*

---

## Decision Tree Model (Excel) - Chemotherapy Vs Immunotherapy to Treat Advanced Melanoma
- [Decision Tree Model](decision-tree-model/Decision-Tree%20Model.xlsx)
